Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Trading 05-10 10:56:38 EDT

15.87

+0.47

+3.05%

High16.00	Low15.18	Vol87.89K
Open15.46	D1 Closing15.40	Amplitude5.32%
Mkt Cap405.22M	Tradable Cap153.15M	Total Shares25.53M
T/O1.38M	T/O Rate0.91%	Tradable Shares9.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":15.87,"timestamp":1715352995030,"preClose":15.4,"halted":0,"volume":87886,"delay":0,"floatShares":9650255,"shares":25533533,"eps":-7.221351,"marketStatus":"Trading","change":0.47,"latestTime":"05-10 10:56:38 EDT","open":15.46,"high":16,"low":15.18,"amount":1378390.9289860001,"amplitude":0.053247,"askPrice":16,"askSize":176,"bidPrice":15.82,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-7.221351,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1715371200000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":15.4,"postHourTrading":{"tag":"盘后","latestPrice":15.4,"preClose":15.4,"latestTime":"16:36 EDT","volume":290,"amount":4466.05,"timestamp":1715286995441},"volumeRatio":2.015063},"requestUrl":"/m/hq/s/LENZ","defaultTab":"news","newsList":[{"id":"2434785017","title":"Shield Therapeutics Reports Revenue Surge and Reduced Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2434785017","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434785017?lang=en_us&edition=fundamental","pubTime":"2024-05-10 22:47","pubTimestamp":1715352446,"startTime":"0","endTime":"0","summary":"Shield Therapeutics (GB:STX) has released an update. Shield Therapeutics PLC, an innovative pharmaceutical company, has reported a significant fina...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/shield-therapeutics-reports-revenue-surge-and-reduced-losses?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/shield-therapeutics-reports-revenue-surge-and-reduced-losses?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434854822","title":"Checkpoint Therapeutics GAAP EPS of -$0.33","url":"https://stock-news.laohu8.com/highlight/detail?id=2434854822","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434854822?lang=en_us&edition=fundamental","pubTime":"2024-05-10 21:46","pubTimestamp":1715348770,"startTime":"0","endTime":"0","summary":"Checkpoint Therapeutics press release  (NASDAQ:CKPT): Q1  GAAP EPS of -$0.33.\nAs of March 31, 2024, Checkpoint’s cash and cash equivalents totaled $11.2 million, compared to $4.9 million at December 31, 2023, an increase of $6.3 million.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104626-checkpoint-therapeutics-gaap-eps-of-0_33","is_publish_highlight":false,"gpt_icon":0},{"id":"2434526851","title":"ADC Therapeutics First Quarter 2024 Earnings: In Line With Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2434526851","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2434526851?lang=en_us&edition=fundamental","pubTime":"2024-05-10 21:25","pubTimestamp":1715347555,"startTime":"0","endTime":"0","summary":"NYSE:ADCT Earnings and Revenue Growth May 10th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue was in line with analyst estimates. Earnings per share  was also in line with analyst expectations.Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.The company's shares are down 3.4% from a week ago.We don't want to rain on the parade too much, but we did also find 4 warning signs for ADC Therapeutics (1 is potentially serious!) that you need to be mindful of.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adc-therapeutics-first-quarter-2024-132555028.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434859970","title":"Edgewise Therapeutics’ New $175M Stock Sale Agreement and Previous Termination","url":"https://stock-news.laohu8.com/highlight/detail?id=2434859970","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434859970?lang=en_us&edition=fundamental","pubTime":"2024-05-10 21:22","pubTimestamp":1715347359,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics (EWTX) has provided an update. Edgewise Therapeutics, Inc. has inked a deal with Leerink Partners LLC to potentially sell up ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/edgewise-therapeutics-new-175m-stock-sale-agreement-and-previous-termination?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/edgewise-therapeutics-new-175m-stock-sale-agreement-and-previous-termination?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434288859","title":"BRIEF-Edgewise Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed - Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2434288859","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434288859?lang=en_us&edition=fundamental","pubTime":"2024-05-10 21:21","pubTimestamp":1715347319,"startTime":"0","endTime":"0","summary":"May 10  - Edgewise Therapeutics Inc   :   * EDGEWISE THERAPEUTICS FILES FOR MIXED SHELF OFFERING, SIZE NOT DISCLOSED - FILING   * EDGEWISE THERAPEUTICS - SALES AGREEMENT PROSPECTUS COVERING OFFERING OF UP TO  $175 MILLION OF COMMON STOCK THAT MAY BE ISSUED UNDER SALES AGREEMENTSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2434598708","title":"Intensity Therapeutics GAAP EPS of -$0.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2434598708","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434598708?lang=en_us&edition=fundamental","pubTime":"2024-05-10 21:01","pubTimestamp":1715346083,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics press release  : Q1  GAAP EPS of -$0.34.INT230-6, Intensity's lead drug candidate, continues to advance into late-stage clinical programs in sarcoma and breast cancer. Cash and investments of $10.5 million expected to fund operations through the end of the first quarter of 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104574-intensity-therapeutics-gaap-eps-of-0_34","is_publish_highlight":false,"gpt_icon":0},{"id":"2434537958","title":"Checkpoint Therapeutics Q1 EPS $(0.33) Misses $(0.27) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2434537958","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2434537958?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:33","pubTimestamp":1715344434,"startTime":"0","endTime":"0","summary":"Checkpoint Therapeutics (NASDAQ:CKPT) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.27) by 22.22 percent. This is a 62.92 percent increase over losses of $(0.89) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38759119/checkpoint-therapeutics-q1-eps-0-33-misses-0-27-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2434537888","title":"Press Release: Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2434537888","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434537888?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:30","pubTimestamp":1715344200,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May 10, 2024  -- Checkpoint Therapeutics, Inc.  , a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2024, and recent corporate updates.James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, \"Over the past few months, we have worked closely with our third-party contract manufacturing organization  for cosibelimab to resolve their inspection deficiencies noted in the complete response letter  we received from the U.S. Food and Drug Administration  last December. Recently, our CMO submitted to FDA their response to the inspection deficiencies, which we believe could allow for the resubmission of our biologics license application . We plan to meet with the FDA shortly, at which time we will seek to reach alignment for a potential mid-year BLA resubmission.\". -- Checkpoint submitted a BLA to the FDA in January 2023 seeking approval of. cosibelimab as a potential new tre","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2434853260","title":"ITeos Therapeutics Q1 2024 GAAP EPS $(1.07) Misses $(1.02) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2434853260","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2434853260?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:27","pubTimestamp":1715344059,"startTime":"0","endTime":"0","summary":"ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(1.02) by 4.9 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38758957/iteos-therapeutics-q1-2024-gaap-eps-1-07-misses-1-02-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2434347855","title":"Buy Rating Affirmed for Century Therapeutics Amid Promising Trials and Strategic Acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2434347855","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434347855?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:15","pubTimestamp":1715343354,"startTime":"0","endTime":"0","summary":"In a report released yesterday, William Maughan from Canaccord Genuity maintained a Buy rating on Century Therapeutics (IPSC – Research Report), wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-century-therapeutics-amid-promising-trials-and-strategic-acquisitions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-century-therapeutics-amid-promising-trials-and-strategic-acquisitions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434589768","title":"Viridian Therapeutics to Participate in Upcoming May Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2434589768","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2434589768?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:00","pubTimestamp":1715342400,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May 10, 2024----Viridian Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in May:. 2024 RBCCM Global Healthcare Conference : Presentation on Tuesday, May 14, 2024, at 8:30 a.m. ET.BofA Securities 2024 Health Care Conference : Presentation on Wednesday, May 15, 2024, at 4:35 p.m. PT.Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor  inhibitors, including VRDN-","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TNPGQ2a_97XmznWHZt1iqQ--~B/aD02MDA7dz0yNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/40a6aafc45a3d42f214dcdf907756665","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TNPGQ2a_97XmznWHZt1iqQ--~B/aD02MDA7dz0yNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/40a6aafc45a3d42f214dcdf907756665"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viridian-therapeutics-participate-upcoming-may-120000514.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434538108","title":"Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2434538108","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2434538108?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:00","pubTimestamp":1715342400,"startTime":"0","endTime":"0","summary":"BOULDER, Colo., May 10, 2024----Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET.The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation. It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1p1Vcc.C3v95oyDY5jbiFA--~B/aD05MTI7dz0yNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/eccae13b7acafc95aed90380457bd3e5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1p1Vcc.C3v95oyDY5jbiFA--~B/aD05MTI7dz0yNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/eccae13b7acafc95aed90380457bd3e5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/edgewise-therapeutics-present-rbc-capital-120000580.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434830091","title":"Aprea Therapeutics Inc    expected to post a loss of 78 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2434830091","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434830091?lang=en_us&edition=fundamental","pubTime":"2024-05-10 19:59","pubTimestamp":1715342347,"startTime":"0","endTime":"0","summary":"* Aprea Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on May 13 (estimated) for the period ending March 31 2024   *    * LSEG's mean analyst estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2434837964","title":"Coya Therapeutics GAAP EPS of -$0.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2434837964","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434837964?lang=en_us&edition=fundamental","pubTime":"2024-05-10 19:31","pubTimestamp":1715340710,"startTime":"0","endTime":"0","summary":"Coya Therapeutics press release  (NASDAQ:COYA): Q1  GAAP EPS of -$0.35.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104492-coya-therapeutics-gaap-eps-of-0_35","is_publish_highlight":false,"gpt_icon":0},{"id":"2434411837","title":"Structure Therapeutics reports Q1 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2434411837","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434411837?lang=en_us&edition=fundamental","pubTime":"2024-05-10 19:22","pubTimestamp":1715340130,"startTime":"0","endTime":"0","summary":"Structure Therapeutics press release  (NASDAQ:GPCR): Q1 Net loss for $26.0 million,\n Cash, cash equivalents and short-term investments totaled $436.4 million on March 31, 2024.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104475-structure-therapeutics-reports-q1-results","is_publish_highlight":false,"gpt_icon":0},{"id":"2434830004","title":"BioXcel Therapeutics First Quarter 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2434830004","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2434830004?lang=en_us&edition=fundamental","pubTime":"2024-05-10 19:21","pubTimestamp":1715340096,"startTime":"0","endTime":"0","summary":"NasdaqCM:BTAI Earnings and Revenue History May 10th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 8.0%. Earnings per share  also missed analyst estimates by 16%.Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.The company's shares are down 10% from a week ago.We should say that we've discovered 7 warning signs for BioXcel Therapeutics (2 are potentially serious!) that you should be aware of before investing here.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioxcel-therapeutics-first-quarter-2024-112136800.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434329834","title":"Astria Therapeutics: A Strong Buy on Innovative HAE Treatment and Strategic Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2434329834","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434329834?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:49","pubTimestamp":1715338165,"startTime":"0","endTime":"0","summary":"In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Astria Therapeutics (ATXS – Research Report), ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/astria-therapeutics-a-strong-buy-on-innovative-hae-treatment-and-strategic-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/astria-therapeutics-a-strong-buy-on-innovative-hae-treatment-and-strategic-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434834311","title":"Century Therapeutics: A Promising Buy Amidst Clinical and Strategic Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2434834311","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434834311?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:47","pubTimestamp":1715338057,"startTime":"0","endTime":"0","summary":"Mitchell Kapoor, an analyst from H.C. Wainwright, maintained the Buy rating on Century Therapeutics (IPSC – Research Report). The associated price ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/century-therapeutics-a-promising-buy-amidst-clinical-and-strategic-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/century-therapeutics-a-promising-buy-amidst-clinical-and-strategic-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434834310","title":"Bullish Outlook: Bioxcel Therapeutics’ Revenue Surge and Promising Clinical Trials Fuel Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2434834310","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434834310?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:47","pubTimestamp":1715338027,"startTime":"0","endTime":"0","summary":"Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Bioxcel Therapeutics (BTAI – Research Report), retaining the price target of $1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bullish-outlook-bioxcel-therapeutics-revenue-surge-and-promising-clinical-trials-fuel-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bullish-outlook-bioxcel-therapeutics-revenue-surge-and-promising-clinical-trials-fuel-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434831571","title":"Rapt Therapeutics Cut to Neutral From Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2434831571","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434831571?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:39","pubTimestamp":1715337540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 10, 2024 06:39 ET (10:39 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0615},{"period":"1month","weight":-0.2491},{"period":"3month","weight":-0.2715},{"period":"6month","weight":-0.0598},{"period":"1year","weight":-0.2903},{"period":"ytd","weight":-0.1603}],"compareEarnings":[{"period":"1week","weight":0.03},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0378},{"period":"6month","weight":0.1806},{"period":"1year","weight":0.2599},{"period":"ytd","weight":0.0944}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license  agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.187611},{"month":2,"riseRate":0.666667,"avgChangeRate":0.15153},{"month":3,"riseRate":0,"avgChangeRate":-0.19103},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.06634},{"month":5,"riseRate":0,"avgChangeRate":-0.184919},{"month":6,"riseRate":0.5,"avgChangeRate":0.042853},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.062127},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.052314},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.028796},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.037137},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.124883},{"month":12,"riseRate":0.666667,"avgChangeRate":0.157581}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}